Surgical versus Medical Castration in the Management of Advanced Prostate Cancer
For centuries the effect of castration on sexuality and the secondary sex glands of man has been known and for the whole of this century orchidectomy has been employed as endocrine therapy for prostatic disorders. It was in 1786 that John Hunter first described scientifically the effect of castration on the prostate gland and at the end of the last century White  and Cabot  advocated, without distinguishing between benign and neoplastic disease, the removal of the testes for prostatic obstruction of the bladder neck. In 1941, Huggins et al.  stated that “in many instances, a malignant prostatic tumour is an overgrowth of adult prostatic epithelial cells. All known types of adult prostatic epithelial cells undergo atrophy when androgenic hormones are greatly reduced in amount. Therefore, significant improvement should occur in the clinical condition of patients with advanced prostatic carcinoma subjected to castration”. The authors observed that, following orchidectomy, patients with advanced prostatic cancer experience relief of pain associated with calcification of lytic bone metastases and a fall in pre-treatment elevated acid phosphatase levels. They also observed that the administration of exogenous testosterone caused a return of symptoms. The only disadvantages of orchidectomy are the psychological stress of the operation, minor surgical complications such as scrotal haematoma or abscess, loss of libido and impotence, hot flushes and occasional transient ankle oedema. Since 1941, because of observations of Huggins, surgical castration has been the standard endocrine treatment against which other therapies have been judged. It was not until the early 1970s that plasma testosterone levels were first measured, demonstrating that castration does remove the principal source of androgens. It was observed that orchidectomy reduced the circulating plasma testosterone by 90% to castrate levels, with the remaining androgens being derived from the adrenal cortex [5,6]. Testosterone is a pro-hormone which is converted in the prostatic cell by 5-alpha reductase to dihydrotestosterone, the active hormone. The significance of dihydrotestosterone derived from adrenal androgens is discussed in other contributions to this monograph, but in spite of its existence it has generally been accepted that in symptomatic advanced prostatic carcinoma 70–80% of patients have a subjective or objective response to castration.
KeywordsPlasma Testosterone Luteinising Hormone Release Hormone Cyproterone Acetate Plasma Testosterone Level Surgical Castration
Unable to display preview. Download preview PDF.
- 1.Hunter J: Observation on Certain Parts of the Animal Oeconomy. First Edition, London 1786 p 39Google Scholar
- 8.Nesbitt RM, Plumb RT: Prostatic carcinoma: a follow-up of 795 patients treated prior to endocrine era and a comparison of survival rates between these patients treated by endocrine therapy. Surgery 1946 (20):263–272Google Scholar
- 9.Veterans Administration Cooperative Urological Research Group: Treatment survival of patients with cancer of the prostate. Surg Gyn Obst 1967 (124):1011–1017Google Scholar
- 10.Robinson MRG: EORTC protocol 30805: a phase III trial comparing orchidectomy versus orchidectomy and cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Smith PH, Pavone-Macaluso M (eds) Management of Advanced Cancer of the Prostate and Bladder. A Liss, New York 1988 pp 101–110Google Scholar
- 13.Denis L, Kuyppens F, Mahler C, Debruyne FMJ, Weil EHJ, Lunglmayr G, Newling D, Robinson MRG, Richards B, Smith PH, Whelan P: Long-term therapy with depot LHRH analogue (Zoladex) in patients with advanced prostatic cancer. In: Murphy GP, Khoury S, Kuss R, Chatelane Ch and Denis L (eds) The Prostate Cancer. Part A: Research, Endocrine Treatment, Histopathology. A Liss, New York 1987 pp 221–228Google Scholar
- 14.Bouffioux C, Denis L, Mahler C, de Laval J: The treatment of advanced prostatic cancer with LHRH analogues: prevention of “flare-up” phenomenon. In: Murphy GP, Khoury S, Kuss R, Chatelane Ch and Denis L (eds) The Prostate Cancer. Part A: Research, Endocrine Treatment, Histopathology. A Liss, New York 1987 pp 255–260Google Scholar
- 15.Peeling WB: A comparison between surgical orchidectomy and LHRH antagonist (“Zoladex” ICI 188630). In: Murphy GP, Khoury S (eds) The Treatment of Metastatic Cancer of the Prostate. Therapeutic Progress in Urological Cancers. A Liss, New York 1989 pp 41–46Google Scholar
- 16.Labrie F, Dupont A, Belanger A, Cusan L, Lacousiere Y, Monfette G, Laberge JG, Emond JP, Fazekas ATA, Raynaud JP, Husson JM: New hormonal therapy in prostatic carcinoma: combined treatment with LHRH agonist and an anti-androgen. J Clin Invest Med 1982 (5):267–275Google Scholar